Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor

No approved therapy exists for cancer‐associated cachexia. The colon‐26 mouse model of cancer cachexia mimics recent late‐stage clinical failures of anabolic anti‐cachexia therapy and was unresponsive to anabolic doses of diverse androgens, including the selective androgen receptor modulator (SARM)...

Descripción completa

Detalles Bibliográficos
Autores principales: Liva, Sophia G, Tseng, Yu‐Chou, Dauki, Anees M, Sovic, Michael G, Vu, Trang, Henderson, Sally E, Kuo, Yi‐Chiu, Benedict, Jason A, Zhang, Xiaoli, Remaily, Bryan C, Kulp, Samuel K, Campbell, Moray, Bekaii‐Saab, Tanios, Phelps, Mitchell A, Chen, Ching‐Shih, Coss, Christopher C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005646/
https://www.ncbi.nlm.nih.gov/pubmed/31930715
http://dx.doi.org/10.15252/emmm.201809910

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005646/
https://www.ncbi.nlm.nih.gov/pubmed/31930715
http://dx.doi.org/10.15252/emmm.201809910

Ejemplares similares